La médecine de précision redéfinit notre approche de la psychiatrie, notamment pour les troubles complexes comme l’autisme GrandAngle, Octobre 11, 2024 – Fondée en 2017 à Genève, STALICLA se distingue comme pionnière dans ce domaine. L’entreprise regroupe une trentaine de médecins chercheurs spécialisés en neuro-sciences et biologie moléculaire, opérant en Suisse, à Barcelone et à Boston. … Read more
Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics July 9, 2024 Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today … Read more
May 8, 2024 Geneva, Switzerland, May 8, 2024 – STALICLA SA, a Swiss neuro precision biotech company, has provided proof-of-concept clinical data for DEPI (Databased Endophenotyping Patient Identification), its neuro precision discovery platform, enabling the identification of biological subgroups of patients with Autism Spectrum Disorder (ASD) and matching treatments, in a study published last week in … Read more
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder May 2, 2024 Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company’s drug-drug interaction (DDI) study of STP7 (Mavoglurant), an … Read more
STALICLA Appoints Dr. Thomas Blaettler, MD Date: Friday, Jan. 19, 2024 GENEVA–(BUSINESS WIRE)– STALICLA SA, a Swiss clinical-stage biotechnology company focused on advancing precision medicine for brain diseases, announced today the appointment of Thomas Blaettler, to the position of Chief Medical Officer. Dr. Thomas Blaettler brings a wealth of pharmaceutical development experience and deep insights … Read more
Stalicla SA Secures $17.4 Million in Series B Funding to Advance Innovative Therapies Subtitle: Funding Enables Progress in Treating Cocaine Misuse Disorder and Autism Spectrum Disorder Date: Friday, Jan. 19, 2024 Source: BioWorld (©2024 BioWorld. Reprinted with permission from Clarivate.) Stalicla SA Achieves First Close of $17.4 Million Series B Round for Therapeutic Development BioWorld, … Read more
STALICLA’s Precision Neuro Advancements propelled by $17.4 Million in Series B Funding Geneva, Switzerland, January 16th, 2024 – STALICLA SA, a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders, announces the successful completion of the first closing of its Series B financing round, securing $17.4 million. Led by SPRIM Global Investments Pte, … Read more
daniel bertholet
Copyright © 2024